Bao Rui Announces Loan Disclosure Under Regulations
NQ Score
43/100
N1 Content Completeness
5
AI Summary (NQ-processed)
Bao Rui and its subsidiaries announced that the outstanding loan balance exceeds 20% of the latest financial statements' net assets, primarily for operational funds needed for acquiring U.S. drug certifications and expanding CDMO businesses.
AI Analysis
Frequently Asked Questions
- Q: What is the main purpose of Bao Rui Company's loans?
- A: The main purpose is to secure operational funds needed for business expansion in the U.S. market, particularly for acquiring drug certification rights and expanding the CDMO business.
- Q: What is the ratio of the outstanding loan balance to net assets?
- A: The outstanding loan balance accounts for 38.61% of the latest financial statements' net assets of the publicly listed company.
- Q: What is the source of Bao Rui Company's loans?
- A: The source of the loans is the subsidiaries themselves.
- Q: Who are the main recipients of Bao Rui Company's loans?
- A: The main recipients include Bora Pharmaceutical Holdings, LLC, Bora Pharmaceuticals USA Inc., Bora Pharmaceuticals Inc., Upsher-Smith Laboratories, LLC, and Bora Pharmaceuticals Injectables Inc.
- Q: What are the loan limits for Bao Rui Company?
- A: The loan limits are 14,176,296 thousand yuan, 3,939,565 thousand yuan, 27,110,314 thousand yuan, 2,464,916 thousand yuan, and 27,110,314 thousand yuan.